· Published by Health Canada · Official notice
This is duplicated text of a letter from the Baxter Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 16, 2013
Dear Customers and Patients,
Subject: Potential for particles from the administration port material being present in CLINOLEIC 20% - Product Codes CJDB9501 250 mL, CJDB9503 500 mL, CJDB9504 1000 mL
Baxter Corporation and Health Canada are providing you this Important Safety Information as there is a possibility of creating particles from the administration port material while the pharmacy prepares your Parenteral Nutrition (PN) prescription using CLINOLEIC 20%.
For any questions regarding the use of filters, please contact your Health Care Professional or Home Care Provider.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected side effects in patients receiving CLINOLEIC 20% should be reported to Baxter Corporation or Health Canada.
Baxter Corporation
7125 Mississauga Rd, Mississauga, Ontario L5N 0C2
1-888-719-9955
canada_productsurveillance@baxter.com
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636
Sincerely,
original signed by
Phil Lynch
Director, Quality,
Baxter Corporation
Baxter and Clinoleic are Registered Trademarks of Baxter International Inc. 2013FCA13